Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
暂无分享,去创建一个
F. Cappuzzo | G. Ceresoli | A. Santoro | I. Garassino | R. Cavina | P. Zucali | F. De Vincenzo | H. S. Soto Parra | S. Salamina | E. Campagnoli
[1] R. Stephens,et al. A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: First results of the Medical Research Council (MRC) / British Thoracic Society (BTS) MS01 trial , 2007 .
[2] J. Sørensen,et al. Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] G. Giaccone,et al. Biology and management of malignant pleural mesothelioma. , 2006, European journal of cancer.
[4] M. van Glabbeke,et al. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Ceribelli,et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Shamash,et al. P-397 Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage , 2005 .
[7] C. Porta,et al. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. , 2005, Lung cancer.
[8] K. Nackaerts,et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] V. Rusch. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Paccagnella,et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma , 2003, Cancer.
[12] G. Scagliotti,et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Schreiber,et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. , 2003, Clinical lung cancer.
[14] T. Chevalier,et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Giaccone,et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. , 2002, European journal of cancer.
[16] D. Fielding,et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma , 2002, British Journal of Cancer.
[17] O. S. Nielsen,et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.
[18] R. V. van Klaveren,et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma , 2002, British Journal of Cancer.
[19] J. V. van Meerbeeck,et al. The role of gemcitabine in the treatment of malignant mesothelioma. , 2002, Seminars in oncology.
[20] J. Shamash,et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Vogelzang. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Giaccone,et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1999, Cancer.
[23] G. Giaccone,et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma , 1999 .
[24] F Levi,et al. The European mesothelioma epidemic , 1999, British Journal of Cancer.
[25] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[26] V. Rusch. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.
[27] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[28] E. Gehan. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.
[29] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[30] J. Shamash,et al. Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma , 2007, Cancer.
[31] Mark R. Green,et al. Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B , 2004, Cancer Chemotherapy and Pharmacology.
[32] I. Smith,et al. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma , 2004, Cancer Chemotherapy and Pharmacology.
[33] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Ducreux,et al. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] A. Musk,et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Bye,et al. Phase II trial of carboplatin in the management of malignant mesothelioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.